Form 4: Insmed Director Clarissa Desjardins Receives RSU Grant
Director Equity Grant Disclosure
Insmed Incorporated director Clarissa Desjardins was granted 3,305 restricted stock units as part of her board compensation.
Summary
- Director Clarissa Desjardins acquired 3,305 restricted stock units (RSUs) of Insmed Incorporated (INSM) common stock.
- The grant occurred on May 13, 2026, for no consideration.
- The RSUs vest in full on the first anniversary of the grant date, subject to continued board service and meeting attendance requirements.
- Following this transaction, the director's direct beneficial ownership increased to 70,312 shares, with an additional 3,025 shares held indirectly by her spouse.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral, routine administrative filing regarding director compensation.
Positives
- Alignment of director interests with shareholders through equity-based compensation.
- Standard retention mechanism via one-year cliff vesting schedule.
Negatives
- None identified; this is a routine compensatory disclosure.
Risks
- Vesting is contingent upon the director remaining on the Board and meeting specific attendance thresholds (at least 75% of meetings).
Future Outlook
The RSUs are scheduled to vest on May 13, 2027, provided the director remains on the board and meets attendance requirements.
Industry Context
StockSavvy.ai notes that equity grants to non-employee directors are standard corporate governance practice in the biotechnology sector to ensure long-term alignment with shareholder value creation.
Comparison to Industry Standards
- The use of RSU grants for board compensation is consistent with standard practices for mid-cap biotechnology companies.
- The one-year vesting period is a common industry benchmark for director equity awards.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney | Clarissa Desjardins appointed Michael A. Smith, Katrina S. Atieh, and Ian S. Macdonald as attorneys-in-fact for SEC reporting purposes. | 08/06/2025 | Standard administrative procedure to ensure timely and compliant SEC filings. |
Stakeholder Impact
- Minimal impact on shareholders; reflects standard director compensation practices.
Next Steps
- Vesting of the 3,305 RSUs on May 13, 2027.
Key Dates
| Date | Description |
|---|---|
| 08/06/2025 | Date of execution for the Limited Power of Attorney. |
| 05/13/2026 | Date of the RSU grant transaction. |
| 05/15/2026 | Date of filing for the Form 4. |
Keywords
Insmed, INSM, Director Compensation, Restricted Stock Units, Insider Ownership, SEC Form 4
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.